NICE
NICE recommendation for AstraZeneca’s Calquence in chronic lymphocytic leukaemia populations
December 8, 2020Manufacturing and Production, Sales and Marketing AstraZeneca, NHS, NICE, UK, leukaemia
The National Institute for Health and Care Excellence (NICE) has recommended that AstraZeneca’s Calquence (acalabrutinib) be used on the NHS in …
NICE recommends Lilly’s Emgality for chronic and episodic migraine
November 18, 2020Research and Development, Sales and Marketing Eli Lilly, NHS, NICE, UK
Eli Lilly’s Emgality (galcanezumab) is set to become an approved option for the prevention of episodic and chronic migraine on …
NICE recommends Sanofi’s Cablivi for ultra-rare acute thrombotic thrombocytopenic purpura
November 12, 2020Sales and Marketing NHS, NICE, Sanofi, pharma
Sanofi’s Cablivi (caplacizumab) has received recommendation from NICE for routine NHS use in England and Wales for the treatment of …
NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia
November 10, 2020Manufacturing and Production, Sales and Marketing AbbVie, NHS, NICE, UK, leukaemia, venetoclax
NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic …
NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer
November 5, 2020Sales and Marketing BMS, Cancer, NHS, NICE, opdivo
NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …
NICE recommends Novo’s liraglutide for management of obesity and non-diabetic hyperglycaemia
October 30, 2020Medical Communications, Sales and Marketing NICE, Novo Nordisk, liraglutide
Novo Nordisk’s pre-filled injection Saxenda (liraglutide) has received the backing of drug watchdog NICE, meaning it will now be made …
NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma
October 16, 2020Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma
Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …
NICE gives go-ahead for Sandoz’s Rizmoic to treat opioid-induced constipation
September 30, 2020Research and Development, Sales and Marketing NHS, NICE, Rizmoic, Sandoz, UK
The National Institute for Health and Care Excellence (NICE) has recommended Sandoz’s Rizmoic (naldemedine) for the treatment of opioid-induced constipation …
Opdivo scores NICE recommendation in two non-small cell lung cancer indications
September 17, 2020Sales and Marketing NICE, lung cancer, opdivo
NICE has announced its recommendation of Bristol-Myers Squibb’s blockbuster immunotherapy drug Opdivo (nivolumab) for the treatment of two non-small cell …
NICE U-turns to approve AstraZeneca’s Tagrisso in two new lung cancer indications
September 11, 2020Medical Communications, Sales and Marketing AstraZeneca, NICE, Tagrisso
NICE has announced the recommendation of AstraZeneca’s Tagrisso (osimertinib) for routine use on the NHS in England and Wales in …
NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant
September 11, 2020Medical Communications, Sales and Marketing Celgene, NICE, Revlimid
It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance of newly diagnosed multiple myeloma …
NICE rejects mycosis fungoides-type cutaneous T-cell lymphoma therapy over data concerns
August 5, 2020Research and Development, Sales and Marketing Ledaga, NICE, lymphoma
NICE has announced its rejection of Ledaga (chlormethine gel), a topical therapy for the treatment of mycosis fungoides-type cutaneous T-cell …
Bavencio+Inylta combo approved or Cancer Drugs Fund in advanced renal cell carcinoma
July 31, 2020Medical Communications, Sales and Marketing Merck, NICE, Pfizer, pharma
NICE has revealed that a combination of Merck KGaA’s Bavencio (avelumab) and Pfizer’s Inlyta (axitinib) will be made available as …
NICE shoots down Kyowa Kirin’s Poteligeo for NHS treatment of mycosis fungoides or Sézary syndrome
July 30, 2020Sales and Marketing Kyowa Kirin, NICE, pharma
NICE has issued draft guidance that has shot down Kyowa Kirin’s therapy Poteligeo (mogamulizumab) for use on the NHS in …
Gilteritinib becomes first NICE-approved oral therapy for relapsed or refractory acute myeloid leukaemia
July 16, 2020Sales and Marketing Atellas, NICE, UK, acute myeloid leukaemia, gilteritinib
NICE has revealed its recommendation of Astellas’ gilteritinib for routine use as a monotherapy on the NHS in England and …
Latest content
FibroFind appoints Lee Borthwick as CEO
